Phase 2 Endometrial Cancer Trial, RecruitingNCT05640999Sponsor: Canadian Cancer Trials GroupCondition: Endometrial Cancer
Printed from Voxsanity (voxsanity.com.au) — NCT05640999 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have had surgery to remove the uterus and both ovaries (with or without lymph node removal), with no visible cancer remaining after surgery.
People diagnosed with uterine (endometrial) cancer at Stage I, II, or III, confirmed by a laboratory test on tissue removed during surgery, including several specific types of this cancer.
People whose general health and ability to carry out daily activities falls within an acceptable range as measured by a standard medical scoring system (ECOG score of 0, 1, or 2 — confirm with trial site if unsure what this means).
People living with HIV who are on effective treatment and whose virus levels were undetectable within the last 6 months.
People aged 18 or older.
People who are able and willing to complete health-related questionnaires in English, French, or another validated language.
People who are able to attend all treatment appointments and follow-up visits at the participating trial centre.
People whose trial treatment can begin within 10 weeks of their surgery.
Who may not be able to join:
People who received chemotherapy before surgery as part of their current endometrial cancer treatment.
People who have previously had radiation therapy to the pelvic area.
People with a history of another cancer, unless it was a non-invasive cancer that was fully removed, a non-melanoma skin cancer that was adequately treated, or another cancer that was treated with the intent to cure and has shown no signs of return for 5 or more years.
People whose scans (before or after surgery) show signs that the cancer has spread to distant parts of the body.
People whose surgical records show cancer cells were found at the edges of the tissue removed during surgery (a "positive surgical margin").
People whose fluid sample taken from the abdominal cavity during surgery (if this was done) showed cancer cells present.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Kathy Han, University Health Network, Princess Margaret Hospital, Toronto ON Canada
South Western Sydney Local Health District, Liverpool, New South Wales
Royal North Shore Hospital, St Leonards, New South Wales
2 946-3130
Calvary Mater Newcastle Hospital, Waratah, New South Wales
Westmead Hospital, Westmead, New South Wales
Mater Research Institute South Brisbane, South Brisbane, Queensland
Monash Medical Centre, Clayton, Victoria
39 594-6666
Frankston Hospital, Frankston, Victoria
The Royal Women's Hospital, Parkville, Victoria
613 834-5356
Canberra Hospital, Garran,
Royal Brisbane and Womens Hospital, Herston,
73 646-8111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT05640999
Sponsor: Canadian Cancer Trials Group
Phase: Phase 2
Status: Recruiting
Condition: Endometrial Cancer
Trial contact: 613-533-6430
More information: https://clinicaltrials.gov/study/NCT05640999
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have had surgery to remove the uterus and both ovaries (with or without lymph node removal), with no visible cancer remaining after surgery.
People diagnosed with uterine (endometrial) cancer at Stage I, II, or III, confirmed by a laboratory test on tissue removed during surgery, including several specific types of this cancer.
People whose general health and ability to carry out daily activities falls within an acceptable range as measured by a standard medical scoring system (ECOG score of 0, 1, or 2 — confirm with trial site if unsure what this means).
People living with HIV who are on effective treatment and whose virus levels were undetectable within the last 6 months.
People aged 18 or older.
People who are able and willing to complete health-related questionnaires in English, French, or another validated language.
People who are able to attend all treatment appointments and follow-up visits at the participating trial centre.
People whose trial treatment can begin within 10 weeks of their surgery.
Who may not be able to join:
People who received chemotherapy before surgery as part of their current endometrial cancer treatment.
People who have previously had radiation therapy to the pelvic area.
People with a history of another cancer, unless it was a non-invasive cancer that was fully removed, a non-melanoma skin cancer that was adequately treated, or another cancer that was treated with the intent to cure and has shown no signs of return for 5 or more years.
People whose scans (before or after surgery) show signs that the cancer has spread to distant parts of the body.
People whose surgical records show cancer cells were found at the edges of the tissue removed during surgery (a "positive surgical margin").
People whose fluid sample taken from the abdominal cavity during surgery (if this was done) showed cancer cells present.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Canadian Cancer Trials Group
Registry
ClinicalTrials.gov
Start date
19 December 2022
Est. completion
31 December 2028
Where this trial is recruiting
🇦🇺 Australia
🇨🇦 Canada
🇫🇷 France
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇿 New Zealand
🇳🇴 Norway
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.